Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance.

OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. The candidate, OSE-127, also known as Effi-7, has successfully completed preclinical studies and the company has completed its manufacturing process, which will enable its progress into clinical trials.

OSE-127 is an antibody aginst the alpha chain of the interleukin-7 receptor, also known as the CD127 receptor. Blocking it aims at preventing the migration of pathogenic T lymphocytes responsible for autoimmune diseases.

The drug is being developed by a French consortium including Bpifrance, the Inserm and Nantes University Hospital. Out of a total €20M funding, €9.1M are provided by Bpifrance to take the immunotherapy to Phase II. After that, the French pharma Servier will have the option to in-license the candidate and take over late-stage development, as outlined in a €272M deal signed last December.

Image via Tefi / Shutterstock



Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.